Xiamen jinhexing Pharmaceutical Co., Ltd – Trademark Portfolio

Entity Type: 99

Xiamen jinhexing Pharmaceutical Co., Ltd holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 16 (Paper Goods) — 2 filings in this category. Currently, 1 trademark is registered. Notable registered marks include WDHCG. The owner is based in Xiamen.

No. 27-1-102, pingyangli

Houxi Town, Jimei District

Xiamen 361000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

WDHCG
WDHCG
Registered 2022
WDHCG
WDHCG
Abandoned 2020

Trademark Classifications

Xiamen jinhexing Pharmaceutical Co., Ltd's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

16
Paper Goods (2 filings)

Paper and cardboard; printed matter; bookbinding material; photographs; stationery

Frequently Asked Questions

How many trademarks does Xiamen jinhexing Pharmaceutical Co., Ltd have?

Xiamen jinhexing Pharmaceutical Co., Ltd has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned.

What trademark classes does Xiamen jinhexing Pharmaceutical Co., Ltd file in?

Xiamen jinhexing Pharmaceutical Co., Ltd files trademarks across 1 Nice Classification class. The most active classes are Class 16 (Paper Goods). Class 16 covers paper and cardboard; printed matter; bookbinding material; photographs; stationery.

What are Xiamen jinhexing Pharmaceutical Co., Ltd's most well-known trademarks?

Xiamen jinhexing Pharmaceutical Co., Ltd's registered trademark portfolio includes well-known marks such as WDHCG. These are among 1 currently registered trademark in the portfolio.

What is Xiamen jinhexing Pharmaceutical Co., Ltd's trademark registration success rate?

Xiamen jinhexing Pharmaceutical Co., Ltd has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.